Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.43 |
| ▸ | NPY1R | P25929 | 9/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.43 |
| ▸ | NPY2R | P49146 | 5/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.36 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038374 | 0.96 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL30855541 | 0.96 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL6038377 | 0.96 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL30197540 | 0.94 | NPY5R (0.43) | NPY4RNPY1RNPY5RNPY2RBACE1 | |
| SCHEMBL31265334 | 0.93 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL15268407 | 0.93 | RXFP1 (0.42) | NPY4RNPY1RNPY5RNPY2RRXFP1 | |
| SCHEMBL15268406 | 0.93 | RXFP1 (0.42) | NPY4RNPY1RNPY5RNPY2RRXFP1 | |
| SCHEMBL30111320 | 0.91 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL30463291 | 0.90 | CPB2 (0.42) | NPY4RNPY1RNPY5RNPY2RRXFP1 | |
| SCHEMBL27637834 | 0.90 | FOLH1 (0.44) | NPY4RNPY1RNPY5RNPY2RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257323-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11865192-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | NPY4R 4570/4885NPY1R 4370/4885NPY5R 4077/4885 |
| US-11865192-B2 | Modified wound dressings | MMP8, CD68, ELANE | NPY4R 4570/4885NPY1R 4370/4885NPY5R 4077/4885 |
| US-12257323-B2 | Modified wound dressings | MMP8, CD68, ELANE | NPY4R 4570/4885NPY1R 4370/4885NPY5R 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.